RevImmune, a privately held biotech company based in Paris, France and 
Bethesda, MD, developing CYT107 (recombinant human Interleukin-7) for 
infectious diseases, sepsis and cancer, announced today that its "ILIAD-7" 
international randomized controlled Phase 2 trial in patients critically ill 
with COVID-19, is now enrolling patients at 5 sites in the U.S. The trial has 
already been under way for some time in the U.K. and France and is about to 
start in Brazil.  

Logo - https://mma.prnewswire.com/media/1196997/RevImmune_Logo.jpg

This ILIAD-7 trial has started enrolling patients at Barnes Jewish 
Hospital-Missouri Baptist Medical Center and Washington University in St. 
Louis, and 4 additional sites: the Cleveland Clinic, Stony Brook University 
Hospital, the University of Florida Medical Center, and Rutgers New Brunswick 
Medical Center. Additional sites are in process.

Dr. Kenneth Remy, physician-scientist at Washington University in St. Louis 
explains, "data over the past few months from our laboratory and a growing body 
of literature from others regarding COVID-19 has demonstrated that patients 
have a sustained and severe loss of lymphocytes with a profound immune 
suppression rather than exclusively a cytokine storm. Patients who succumb to 
COVID-19 have the most severe loss of lymphocytes and have a high incidence of 
developing secondary hospital-acquired infections."  

Dr. Vidula Vachharajani, Professor of Medicine, Cleveland Clinic Lerner College 
of Medicine, stated that "IL-7 offers a potential new way to restore immunity 
in COVID-19 patients and may reduce the incidence of secondary hospital 
acquired infections."  

To date, CYT107 has been administered in clinical trials to over 500 patients 
with diverse infectious diseases, sepsis and cancers, with an excellent safety 
profile and encouraging results. The primary mechanism of action of CYT107 
works to restore lymphocyte function and increase lymphocyte proliferation of 
lymphocytes thereby aiding in the elimination of invading pathogens. 

Early success with CYT107 in critically ill COVID-19 patients, published in the 
Journal of American Medical Association (JAMA) Open Network in August, showed 
that CYT 107 improved absolute lymphocyte counts in 12 compassionate use 
patients with COVID-19.   

The CYT107 treatment being tested in the current phase 2 randomized controlled 
trial is designed to improve survival in critically ill patients with hypoxemia 
and severe lymphopenia (low lymphocyte counts). The study is currently 
enrolling at 5 sites in the U.S., and is expected to continue through December.

SOURCE  RevImmune Inc

CONTACT: Dr. Michel Morre, Chief Scientific Officer, mmorre@revimmune.com